» Articles » PMID: 19380872

Hepcidin, the Hormone of Iron Metabolism, is Bound Specifically to Alpha-2-macroglobulin in Blood

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2009 Apr 22
PMID 19380872
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Hepcidin is a major regulator of iron metabolism. Hepcidin-based therapeutics/diagnostics could play roles in hematology in the future, and thus, hepcidin transport is crucial to understand. In this study, we identify alpha2-macroglobulin (alpha2-M) as the specific hepcidin-binding molecule in blood. Interaction of 125I-hepcidin with alpha2-M was identified using fractionation of plasma proteins followed by native gradient polyacrylamide gel electrophoresis and mass spectrometry. Hepcidin binding to nonactivated alpha2-M displays high affinity (Kd 177 +/- 27 nM), whereas hepcidin binding to albumin was nonspecific and displayed nonsaturable kinetics. Surprisingly, the interaction of hepcidin with activated alpha2-M exhibited a classical sigmoidal binding curve demonstrating cooperative binding of 4 high-affinity (Kd 0.3 microM) hepcidin-binding sites. This property probably enables efficient sequestration of hepcidin and its subsequent release or inactivation that may be important for its effector functions. Because alpha2-M rapidly targets ligands to cells via receptor-mediated endocytosis, the binding of hepcidin to alpha2-M may influence its functions. In fact, the alpha2-M-hepcidin complex decreased ferroportin expression in J774 cells more effectively than hepcidin alone. The demonstration that alpha2-M is the hepcidin transporter could lead to better understanding of hepcidin physiology, methods for its sensitive measurement and the development of novel drugs for the treatment of iron-related diseases.

Citing Articles

What are the main proteins in the hemolymph ticks?.

Li D, Liu L, Liu Z, Tian Y, Gao X, Cheng T Front Vet Sci. 2024; 11:1387719.

PMID: 39086760 PMC: 11289883. DOI: 10.3389/fvets.2024.1387719.


ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis.

Duminuco A, Chifotides H, Giallongo S, Giallongo C, Tibullo D, Palumbo G Cancers (Basel). 2024; 16(1).

PMID: 38201581 PMC: 10778144. DOI: 10.3390/cancers16010154.


LncRNA modulates Hippo-YAP signaling to reprogram iron metabolism.

He X, Fan X, Qu L, Wang X, Jiang L, Sang L Nat Commun. 2023; 14(1):2253.

PMID: 37080959 PMC: 10119135. DOI: 10.1038/s41467-023-37871-5.


Genome-wide identification of antisense lncRNAs and their association with susceptibility to in rainbow trout.

Ali A, Salem M Front Immunol. 2022; 13:1050722.

PMID: 36561762 PMC: 9763276. DOI: 10.3389/fimmu.2022.1050722.


Polycystic ovary syndrome and iron overload: biochemical link and underlying mechanisms with potential novel therapeutic avenues.

Mathew M, Sivaprakasam S, Phy J, Bhutia Y, Ganapathy V Biosci Rep. 2022; 43(1).

PMID: 36408981 PMC: 9867939. DOI: 10.1042/BSR20212234.